RASP (Actavia Life Sciences) Total Liabilities: $2.23 Mil (As of Mar. 2024)


What is Actavia Life Sciences Total Liabilities?

Actavia Life Sciences RASP -87.50% Total Liabilities is $2.23 Mil as of Mar. 2024.

Actavia Life Sciences's Total Liabilities for the quarter that ended in Mar. 2024 was $2.23 Mil.

Actavia Life Sciences's quarterly Total Liabilities increased from Sep. 2023 ($2.05 Mil) to Dec. 2023 ($2.13 Mil) and increased from Dec. 2023 ($2.13 Mil) to Mar. 2024 ($2.23 Mil).

Actavia Life Sciences's annual Total Liabilities declined from Sep. 2021 ($2.80 Mil) to Sep. 2022 ($1.77 Mil) but then increased from Sep. 2022 ($1.77 Mil) to Sep. 2023 ($2.05 Mil).

Actavia Life Sciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Total Liabilities Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.41 2.71 2.80 1.77 2.05

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.92 2.01 2.05 2.13 2.23

Actavia Life Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Actavia Life Sciences's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.052+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.05

Total Liabilities=Total Assets (A: Sep. 2023 )-Total Equity (A: Sep. 2023 )
=0.096--1.956
=2.05

Actavia Life Sciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.23+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.23

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=0.049--2.182
=2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.23 Mil mean?
Actavia Life Sciences (RASP) has a Total Liabilities of $2.23 Mil as of Mar. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Total Liabilities too high?
Actavia Life Sciences' current Total Liabilities is $2.23 Mil.
How does Actavia Life Sciences' Total Liabilities compare to BWV and FNCH?
Actavia Life Sciences' Total Liabilities of $2.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Actavia Life Sciences and its competitors. Actavia Life Sciences's current Total Liabilities is $2.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Total Liabilities of $2.23 Mil. The current Total Liabilities is $2.23 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Total Liabilities is $2.23 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.